February 24, 2026
We are excited to announce the publication of Cell Therapy & Immunomodulation Sector for Type 1 Diabetes, JDCA's first comprehensive report on companies in an advanced stage of cure research. It is the first of its kind to combine both a financial and diabetes impact assessment.
In recent years, the T1D research landscape has evolved substantially. There is increasing activity and capital coming from large and early-stage companies toward T1D curative research, shifting from the nonprofit to the commercial sector.
This overview provides a comprehensive understanding of the research landscape from a new angle. It also reflects JDCA's expanding coverage to provide a complete look at the state of the cure.
A few highlights include:
- Insight into 23 companies developing a full or partial Practical Cure—testing a cell supply and/or protection solution.
- In-depth analysis of each company, including 2025 performance, upcoming milestones, and future company outlook.
- An industry overview and market analysis of the growing for-profit interest in T1D curative therapies.
- Investment standpoint and recommendations for selected companies.
